Results 11 to 20 of about 236,981 (311)

Efficiency of a dexamethasone nanosuspension as an intratympanic injection for acute hearing loss

open access: yesDrug Delivery, 2022
Dexamethasone sodium phosphate (Dex-SP) is the most commonly used drug administered via intratympanic injection for the treatment of acute hearing loss, but its penetration efficiency into the inner ear is very low.
So-Young Jung   +7 more
doaj   +1 more source

The Effect of Dexamethasone Treatment on COVID-19 Prognosis in Cancer Patients

open access: yesVaccines, 2022
Background: Dexamethasone is used to treat cancer, relieve chemotherapy-induced nausea and vomiting, enhance cancer patients’ appetites, and treat COVID-19 patients. There is little evidence of the impact of a dexamethasone treatment plan on the severity
Lina Souan   +4 more
doaj   +1 more source

The effect of dilution with glucose and prolonged injection time on dexamethasone-induced perineal irritation – A randomized controlled trial

open access: yesOpen Medicine, 2022
Dexamethasone can be used to prevent nausea and vomiting after surgery, but there is concern that it may induced perineal irritation. The aim of this study was to investigate the attenuation effect of dilution and slow injection on dexamethasone-induced ...
Zhang Yonghai   +8 more
doaj   +1 more source

Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis

open access: yesJournal of Microbiology, Immunology and Infection, 2021
Objective: We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy. Methodology: We performed a retrospective comparative study.
Eduardo Pérez-Alba   +7 more
doaj   +1 more source

Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19

open access: yesFrontiers in Immunology, 2023
IntroductionSevere COVID-19 is characterized by cytokine storm, an excessive production of proinflammatory cytokines that contributes to acute lung damage and death.
Ameet A. Chimote   +7 more
doaj   +1 more source

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

open access: yesHaematologica, 2016
Pomalidomide + low-dose dexamethasone is effective and well tolerated for refractory or relapsed and refractory multiple myeloma after bortezomib and lenalidomide failure.
Katja C. Weisel   +22 more
doaj   +1 more source

Dexamethasone and Dexamethasone Phosphate: Effect on DMPC Membrane Models

open access: yesPharmaceutics, 2023
Dexamethasone (Dex) and Dexamethasone phosphate (Dex-P) are synthetic glucocorticoids with high anti-inflammatory and immunosuppressive actions that gained visibility because they reduce the mortality in critical patients with COVID-19 connected to assisted breathing.
Candelaria Ines Cámara   +3 more
openaire   +4 more sources

Dexamethasone enhances osteogenic differentiation of bone marrow- and muscle-derived stromal cells and augments ectopic bone formation induced by bone morphogenetic protein-2. [PDF]

open access: yesPLoS ONE, 2015
UNLABELLED:We evaluated whether dexamethasone augments the osteogenic capability of bone marrow-derived stromal cells (BMSCs) and muscle tissue-derived stromal cells (MuSCs), both of which are thought to contribute to ectopic bone formation induced by ...
Masato Yuasa   +10 more
doaj   +1 more source

The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Analysis

open access: yesFrontiers in Medicine, 2021
Objective: To compare the therapeutic efficacies of high dose dexamethasone, prednisone and rituximab in combination with dexamethasone for newly diagnosed ITP (Immune Thrombocytopenia, ITP) patients.Methods and results: Relevant publications for this ...
Qirong Xiao   +8 more
doaj   +1 more source

Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis

open access: yesFrontiers in Medicine, 2022
BackgroundSevere COVID-19 pneumonia requiring intensive care treatment remains a clinical challenge to date. Dexamethasone was reported as a promising treatment option, leading to a reduction of mortality rates in severe COVID-19 disease.
Peter Jirak   +18 more
doaj   +1 more source

Home - About - Disclaimer - Privacy